|
|
 |
 |
104. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft 2006
Abstract
Abstract
FR.03.16 Combined intravitreal Avastin (IVA) and photodynamic therapy (PDT) for age-related macular degeneration Eter N., Ladewig M. S., Hamelmann V., Helb H.-M., Karl S., Holz F. G.
Universitäts-Augenklinik Bonn Objective: To evaluate safety and efficacy of same-day administration of intravitreal Avastin (IVA) and photodynamic therapy (PDT) for choroidal neovascularizations (CNV) in age-related macular degeneration (AMD).
Methods: Thirty patients with predominantly classic, minimally classic, or occult CNV due to AMD were treated with PDT. Within one hour after PDT patients received an intravitreal injection of 1.5 mg Bevacizumab (Avastin). At baseline as well as 4 and 12 weeks after treatment ETDRS visual acuity was determined and patients were examined by optical coherence tomography (OCT) and fluorescein angiography (FA).
Results: Four weeks after treatment 96.7% of patients (29 patients) lost less than 15 ETDRS letters. Stabilization or improvement in VA defined as a gain of ³0 ETDRS letters was observed in 77% of patients. Mean visual acuity increased by 3 and 5 ETDRS letters 4 and 12 weeks after therapy, respectively. Mean retinal thickness on OCT decreased by 205 µm and 158 µm 4 and 12 weeks after treatment (p<0.001). There were no ocular or systemic adverse effects noted. Particularly, no intraocular inflammation occurred.
Conclusions: These short-term results indicate that same-day combination of PDT and intravitreal Avastin is a safe and efficacious therapeutic option in neovascular AMD. Further evaluation will address the hypotheses of better functional outcomes and reduced retreatment rates of combined therapy compared to anti-VEGF-monotherapy.
Zurück | Back
|
